New Genetic Data Connect Acne to Inflammatory Bowel Disease

Patients with acne vulgaris (AV) may carry more than a skin-deep condition. New genetic research suggests that acne and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), share underlying immune pathways, helping explain why these conditions often occur together.¹

The key takeaway: this link does not appear to be driven by acne treatments like isotretinoin, as once thought. Instead, acne itself may reflect a broader, systemic inflammatory profile.

A Meaningful Genetic Overlap

Researchers analyzed large genome-wide association study (GWAS) datasets, including more than 34,000 patients with acne and over 30,000 with IBD. While the overall genetic correlation between the conditions was modest, deeper analysis revealed more substantial overlap.

Approximately 25% of acne-related genetic variants were also associated with IBD. In total, investigators identified 36 shared genetic regions, most of which had not previously been linked to acne. Notably, many of these shared variants had concordant effects, meaning they increase risk for both acne and IBD in the same direction.

This helps move the conversation beyond coincidence or treatment effects and toward a shared disease biology.

Immune System at the Center

The overlap between acne and IBD appears to be driven by the immune system—particularly T cells, which play a central role in inflammation.

The shared genetic signals were most active in:

• Blood and immune tissues (like the spleen)
• The skin
• The gastrointestinal tract

More specifically, the study pointed to CD4+ T cells and regulatory T cells, which help control inflammation but can become dysregulated in chronic disease.

JAK-STAT Pathway Emerges as a Key Link

One pathway stood out: JAK-STAT signaling, a major regulator of immune responses.

This is clinically relevant:

• JAK inhibitors are already used in IBD treatment
• Acne-like eruptions have been reported as a side effect of these medications
• Early data suggest increased JAK activity in acne lesions

Together, this supports the idea that targeting shared pathways may influence both conditions—for better or worse.

Other Inflammatory Signals Overlap

The study also highlighted several cytokine pathways familiar to dermatology clinicians:

• IL-12 and IL-23 (linked to Th1/Th17 inflammation)
• IL-13 (involved in skin barrier and keratinocyte changes)
• IL-10 (an anti-inflammatory cytokine with protective effects)

These pathways are already targets in IBD—and in some cases, off-label or emerging targets in severe acne.²

The Bigger Picture

This study adds to a growing body of evidence positioning acne within a broader inflammatory spectrum. The identification of shared genes, immune cells, and signaling pathways—especially those involving T cells and cytokines—suggests that acne and IBD are connected at a fundamental biological level.

While more research is needed, particularly in more diverse populations, these findings may eventually support more targeted, pathway-based approaches to treatment.

What this Means in Practice

For APPs managing acne:

• Be aware of the increased association with IBD, especially in patients with GI symptoms
• Recognize that acne may reflect systemic inflammation, not just a localized skin issue
• Watch for acneiform eruptions in patients on JAK inhibitors

At the same time, this research does not suggest changing standard acne treatments based on IBD risk alone.

Bottom Line

Acne and IBD appear to share a common immune-driven foundation, centered on T-cell activity and cytokine signaling. While more research is needed, this study strengthens the view of acne as part of a broader inflammatory spectrum—and may eventually open the door to more targeted, pathway-based therapies.

References

1. Witkam WCAM, Smak Gregoor AM, van Straalen KR, et al. The shared genetic architecture between acne vulgaris and inflammatory bowel disease: a cross-trait analysis. J Invest Dermatol. Published online April 29, 2026. doi:10.1016/j.jid.2026.03.041
2. Verstockt B, Salas A, Sands BE, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20(7):433-446. doi:10.1038/s41575-023-00768-1